Hemophilia News and Research

RSS

Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.

Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the Israeli Ministry of Health to initiate a Phase IIa clinical study evaluating the safety and efficacy of sustained erythropoietin therapy produced and delivered by the Company's EPODURE Biopumps.

26 Mar 2012

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

16 Mar 2012

TSRI, OPKO Health to develop and commercialize SR 3306 for Parkinson's

OPKO Health, Inc. and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

New FDA approved drug to treat infants with respiratory distress syndrome

Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

7 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies.

From Baxter International Inc. 3 Mar 2012

CSL Behring to receive 2012 EURORDIS Award for pioneering work

CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions.

2 Mar 2012

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 28 February 2012 to review the Group's results for 2011, published today.

29 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Samsung Biologics and Biogen Idec announced today that the companies have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars in keeping with their agreement announced in December.

28 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin.

16 Feb 2012

U-M's first human embryonic stem cell line to be placed on the U.S.NIH registry

The University of Michigan's first human embryonic stem cell line will be placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.

15 Feb 2012

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.

14 Feb 2012

New cERD method can detect RNAi activity in biological fluids

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics.

10 Feb 2012

CSL Behring announces results of rIX-FP Phase I study on hemophilia B

CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B.

3 Feb 2012